Volume 3.49 | Dec 15

Cord Blood News 3.49, December 15, 2011
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Human Umbilical Cord Blood Cells Protect Oligodendrocytes from Brain Ischemia through Akt Signal Transduction
Using both in vitro and in vivo paradigms, this study examined the role of Akt signaling and peroxiredoxin 4 expression in human umbilical cord blood cell-mediated protection of oligodendrocyte from ischemic conditions. [J Biol Chem] Abstract

Try Our New STEMvision App!
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Characteristics of Borrelia hermsii Infection in Human Hematopoietic Stem Cell-Engrafted Mice Mirror Those of Human Relapsing Fever
Researchers examined Borrelia hermsii infection in human hematopoietic stem cell-engrafted nonobese diabetic/SCID/IL-2Rγnull mice: “human immune system mice”. [Proc Natl Acad Sci USA]
Abstract | Press Release

Rapamycin Combined with TGF-β Converts Human Invariant NKT Cells into Suppressive Foxp3+ Regulatory Cells
In this study, researchers report that invariant NKT (iNKT) cells can express Foxp3 once they have been exposed to TGF-β. Foxp3 was expressed by iNKT cells from both peripheral and cord blood. [J Immunol] Abstract

Human Umbilical Cord Blood-Derived Stromal Cells Regulate the Foxp3 Expression of Regulatory T Cells through the TGF-β1/Smad3 Pathway
Researchers isolated a novel population from among CD34+ cells in their laboratory, referred to as human umbilical cord blood-derived stromal cells, which exert an immunosuppressive effect and can notably increase Foxp3 expression in regulatory T cells. [Cell Biochem Biophys]

Valproic Acid Affects the Engraftment of TPO-Expanded Cord Blood Cells in NOD/SCID Mice
Researchers evaluated the effect of valproic acid, in combination with thrombopoietin (TPO), on the viability and expansion of cord blood-hematopoietic stem and progenitor cells and on short- and long-term engraftability in the NOD/SCID mouse model. [Exp Cell Res] Abstract

Hematopoietic Stem Cell Expansion Facilitates Multilineage Engraftment in a Nonhuman Primate Cord Blood Transplantation Model
Researchers wished to establish a nonhuman primate cord blood transplantation model that would allow them to test various hematopoietic stem cell expansion and gene therapy strategies. [Exp Hematol] Abstract

Hematopoietic and Myeloprotective Activities of an Acidic Angelica sinensis Polysaccharide on Human CD34+ Stem Cells
This study aimed to separate and identify the major hematopoietic fraction from Angelica sinensis polysaccharides (ASPS), and to investigate the myeloprotective activity of the major bioactive fraction of ASPS as a possible supporting agent for cancer treatments. [J Ethnopharmacol] Abstract

Effects of Mixed Feeder Cells on the Expansion of CD34+ Cells
Synergistic effects of mesenchymal stem cells isolated from bone marrow, umbilical cord blood and periosteum, and fibroblasts as mixed feeder cells on the expansion of hematopoietic progenitor cells were investigated in serum- and exogenous cytokine-free conditions. [J Biosci Bioeng] Abstract

A Novel Potent Fas Agonist for Selective Depletion of Tumor Cells in Hematopoietic Transplants
Here scientists propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. [Blood Cancer J] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.


Therapy Improves Stem Cell Engraftment in Umbilical Cord Blood Transplant Recipients
A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases. [Press release from the Dana-Farber Cancer Institute discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release

Fate Therapeutics Announces Promising Data from Phase Ib Study of ProHema
Fate Therapeutics, Inc. announced promising clinical results from a Phase Ib trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy. [Press release from Fate Therapeutics, Inc. discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release

Study Points to Novel Way to Improve Outcomes from Umbilical Cord Blood Transplants
A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient’s body than with a conventional cord blood transplant procedure. [Press release from the Perelman School of Medicine at the University of Pennsylvania discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release

Phacilitate Cell and Gene Therapy Forum 2012


Stem Cell and Gene Therapy for Sickle Cell and Other Genetic Diseases
A cure for sickle cell anemia and other life-threatening genetic disorders that arise in the blood is the goal of a new $6.7-million, five-year research project headed by UCSF scientist Y. W. Kan. [The University of California, San Francisco (UCSF)] Press Release

CIRM Approves $27 Million for Initiatives to Accelerate Promising Stem Cell Research Projects
The California Institute for Regenerative Medicine (CIRM) enhanced its efforts to proactively discover and fund innovative research and to provide continuous support to successful research programs, speeding the development of new stem cell-based therapies. [California Institute for Regenerative Medicine] Press Release

Maryland Stem Cell Research Commission Issues Supplement to FY 2012 RFAs – Collaborative Research Opportunity with the California Institute for Regenerative Medicine
The Maryland Stem Cell Research Commission announced the second year of a pilot a program that provides an opportunity for collaboration with the California Institute for Regenerative Medicine. [The Maryland Stem Cell Research Fund] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Centre for Regenerative Medicine: Driving Stem Cell Research Towards Therapy
May 21-22, 2012
Edinburgh, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Laboratory Technician – Cord Blood Processing (Perkin Elmer)

Laboratory Supervisor – Cellular Therapy (NewYork-Presbyterian Hospital)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us